医疗保健及生命科学
医疗健康是一个受到全球趋势、技术创新、当地市场条件、人口特征和法规影响的行业。
亚洲市场的投资和行业整合主要受到以下几点因素的推动：
- 可支配收入的增长以及快速变化的人口结构
- 区域性和生理性的差异化特征
- 公共卫生体系的演变
- 医疗及生物技术创新领导者的不断涌现
全球医疗行业参与者们都开始进入不断壮大的亚洲新兴市场，同时区域性领先企业和投资机构对于在亚洲和欧美间的双向并购机会兴趣增大。
BDA医疗健康团队凭借强大的本土项目执行能力、对于亚洲地区的独特洞察，加之全球化视野以及的丰富的交易经验，为企业客户、投资者以及初创企业提供广泛的战略发展及公司融资交易服务。我们的经验覆盖医疗服务、医疗技术、生物制药、医药外包服务（CRO、CDMO）、消费健康以及动植物生命科学等领域。
Andrew Huntley
Managing Partner, Head of Healthcare
invested in
a portfolio company of
2025
医疗
has divested strategic stake to
2025
医疗
divested majority stake in
to
2024
医疗
acquired majority stake in
2024
医疗
has been acquired by
2023
医疗
received investment from
2023
医疗
a subsidiary of
has acquired
2022
医疗
a portfolio company of
has been acquired by
2022
医疗
agreed to divest East Syracuse, New York facility to
2022
医疗
has sold minority stake to
2022
消费品
出售给Novo Holdings
2022
医疗
investment from
2021
医疗
has been acquired by
2021
医疗
a portfolio company of
has been acquired majority stake by
2021
医疗
拟出售给迈瑞医疗
2021
医疗
divested majority stake to
DCP Capital
2021
医疗
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
医疗
raised Series B round from
2021
医疗
出售尼奥斯给松柏投资
2020
医疗
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
医疗
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
医疗
majority sale
2019
医疗
LAP Lasers a portfolio company of
has been acquired by
2019
医疗
divested majority stake to
2019
医疗
a portfolio company of
has been acquired by
AGIC and Humanwell
2017
医疗
recapitalized majority by
2017
医疗
divested CMC Biologics to
2017
医疗
has been acquired by a Japanese chemicals & life science company
2016
医疗
acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
2013
医疗
divested Radiant Research Inc, US-based clinical research company
2012
医疗